Leave a Message
We will call you back soon!
Your message must be between 20-3,000 characters!
Please check your E-mail!
More information facilitates better communication.
Submitted successfully!
We will call you back soon!
Leave a Message
We will call you back soon!
Your message must be between 20-3,000 characters!
Please check your E-mail!
April 28, 2021
WHO recommends strengthening lab services to meet a goal of testing 70% of women by 2030.
Global cases of cervical cancer are projected to rise from 570,000 to 700,000 between 2018 and 2030, with annual deaths increasing to 400,000 over the next 10 years. Most affected women are young, poor, and undereducated.
WHO proposed some activities to support countries in expanding testing services for cervical cancer screening and diagnosis, like:
· Introduce simplified testing strategies for screening and diagnosis, linked to treatment uptake.
· Create demand for screening and diagnosis services for cervical cancer, involve community partners.
· Streamline procurement, training, and quality assurance across all national testing services.
· Coordinate forecasting efforts for reagents/analyzers/consumables led by national authorities and implementing partners.
In any case, we are likely to have a greater impact on update/demand for screening and diagnosis if testing can be done quickly and accurately.
MORE DETAIL ABOUT WOMEN’S HEALTH RAPID TEST: http://www.alltests.com.cn
Hangzhou AllTest Biotech CO.,LTD | |
#383, Qiaoxin Road, Xiasha Street, Qiantang Disctrict, Hangzhou, Zhejiang, P.R.China | |
86-571-56267891 | |
selina.wu@alltests.com.cn |
China Good Quality Custom Monoclonal Antibody Supplier. © 2014 - 2025 custom-monoclonalantibody.com. All Rights Reserved.